Asmanex Hfa

Dermatophytosis, Asthma, Itching + 14 more

Treatment

2 FDA approvals

20 Active Studies for Asmanex Hfa

What is Asmanex Hfa

Mometasone furoate

The Generic name of this drug

Treatment Summary

Mometasone furoate is a steroid medication that is used to treat asthma, nasal allergies, and certain skin conditions. The drug has a strong binding affinity to the glucocorticoid receptor and is more powerful than many other corticosteroids. It is available as a dry powder inhaler, nasal spray, or ointment.

Elocon

is the brand name

image of different drug pills on a surface

Asmanex Hfa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Elocon

Mometasone furoate

1987

114

Approved as Treatment by the FDA

Mometasone furoate, also known as Elocon, is approved by the FDA for 2 uses including Asthma and Asthma .

Asthma

Helps manage Asthma

Asthma

Helps manage Asthma

Effectiveness

How Asmanex Hfa Affects Patients

Mometasone is a synthetic corticosteroid that works to reduce inflammation. It is 22 times more powerful than dexamethasone and has a lower affinity to mineralocorticoid receptors, making it more selective in its action. When taken, the drug is able to pass through cell membranes and activate pathways that reduce inflammation.

How Asmanex Hfa works in the body

In asthma, mometasone works by blocking the activity of cells involved in inflammation, such as mast cells, eosinophils, basophils, and lymphocytes. It also prevents the release of molecules that cause inflammation, like histamine and leukotrienes. Mometasone is particularly effective because it binds to receptors in cells 22 times more strongly than other corticosteroids. This binding causes the receptors to move to the cell’s nucleus, where they dimerize and bind to DNA sequences that reduce inflammation. Mometasone also blocks transcription factors like activator-protein-1 and

When to interrupt dosage

The suggested measure of Asmanex Hfa is contingent upon the diagnosed condition, for example Dermatitis, Eczematous brought about by shallow Fungal skin contamination, Psoriasis and Skin Diseases, Eczematous. The amount additionally shifts as per the method of delivery (e.g. Powder or Topical) indicated in the table underneath.

Condition

Dosage

Administration

Dermatophytosis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Asthma

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Itching

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Atopic Dermatitis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

prophylaxis of seasonal Allergic rhinitis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Hay Fever

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Seasonal Allergies

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Psoriasis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Psoriasis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Skin Diseases, Eczematous

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Communicable Diseases

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Systemic Treatment

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Nasal Decongestants

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Communicable Diseases

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Bacterial Infections

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Psoriasis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Dermatitis

, 0.001 mg/mg, 1.0 mg/mL, 0.05 mg, 0.22 mg, 0.11 mg, 0.1 %, 0.2 mg, 0.1 mg, 1.35 mg, 0.01 mg/mg, 1.0 mg, 0.32 mg, 0.08 mg, 0.16 mg, 0.0625 mg, 0.1275 mg, 0.26 mg, 0.136 mg, 0.1 mg/pump actuation, 0.05 mg/spray, 0.2 mg/pump actuation, 0.05 mg/pump actuation, 0.4 mg/pump actuation, 0.025 mg

Ointment - Topical, Topical, , Lotion, Lotion - Topical, Ointment, Nasal, Spray, metered, Inhalant - Respiratory (inhalation), Inhalant, Respiratory (inhalation), Cream, Cream - Topical, Solution - Topical, Solution, Aerosol, metered - Respiratory (inhalation), Aerosol, metered, Aerosol - Respiratory (inhalation), Aerosol, Intrasinal, Implant - Intrasinal, Kit, Powder - Respiratory (inhalation), Powder, Spray, metered - Nasal, Capsule, Capsule - Respiratory (inhalation), Implant, Kit - Topical, Spray, Spray - Nasal

Warnings

Asmanex Hfa has six contraindications and should not be taken when encountering the conditions indicated in the following table.

Asmanex Hfa Contraindications

Condition

Risk Level

Notes

Asthma

Do Not Combine

Status Asthmaticus

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Mometasone Furoate may interact with Pulse Frequency

There are 20 known major drug interactions with Asmanex Hfa.

Common Asmanex Hfa Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Mometasone furoate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Mometasone furoate.

Aldesleukin

Major

The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Mometasone furoate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Mometasone furoate.

Almotriptan

Major

The metabolism of Almotriptan can be decreased when combined with Mometasone furoate.

Asmanex Hfa Toxicity & Overdose Risk

Taking too much of a mometasone furoate inhaler may cause long-term side effects like increased cortisol levels and adrenal suppression. Animal studies of pregnant patients have shown that the drug may have toxic effects on fetuses, but humans may be less sensitive. It is unknown if mometasone furoate is found in breast milk, so use caution when giving to nursing mothers. Clinical trials in kids have shown that the inhaler is generally safe and effective, although growth may be slowed by 1cm per year depending on dose and duration of treatment. Elderly patients may be more sensitive to the effects of the inhal

image of a doctor in a lab doing drug, clinical research

Asmanex Hfa Novel Uses: Which Conditions Have a Clinical Trial Featuring Asmanex Hfa?

279 active studies are evaluating the potential of Asmanex Hfa to alleviate Atopic Dermatitis, Seasonal Allergies and Psoriasis.

Condition

Clinical Trials

Trial Phases

Asthma

87 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3

Dermatophytosis

0 Actively Recruiting

Systemic Treatment

0 Actively Recruiting

Seasonal Allergies

0 Actively Recruiting

Itching

4 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1

Hay Fever

0 Actively Recruiting

Skin Diseases, Eczematous

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Psoriasis

0 Actively Recruiting

prophylaxis of seasonal Allergic rhinitis

0 Actively Recruiting

Dermatitis

0 Actively Recruiting

Psoriasis

0 Actively Recruiting

Psoriasis

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Nasal Decongestants

8 Actively Recruiting

Early Phase 1, Phase 4, Not Applicable, Phase 3, Phase 2

Atopic Dermatitis

15 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Phase 1

Communicable Diseases

0 Actively Recruiting

Asmanex Hfa Reviews: What are patients saying about Asmanex Hfa?

4.3

Patient Review

9/10/2021

Asmanex Hfa for Asthma

This treatment unfortunately caused me to develop a cough, runny nose, and swollen nose.

4.3

Patient Review

3/23/2016

Asmanex Hfa for Asthma

2.3

Patient Review

8/28/2017

Asmanex Hfa for Asthma

2

Patient Review

3/11/2017

Asmanex Hfa for Asthma

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about asmanex hfa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Asmanex HFA a steroid?

"Yes, Asmanex can help to control asthma symptoms and prevent asthma attacks from happening. It is not however a rescue medication that can be used during an active asthma attack."

Answered by AI

How many times a day can you use Asmanex?

"Other options for patients who don't respond well to the initial dosage after 2 weeks are to either increase the dosage or change the therapy. The maximum daily recommended dose for ASMANEX HFA is two inhalations, 200 mcg each, for a total of 400 mcg a day."

Answered by AI

What is Asmanex HFA used for?

"ASMANEX HFA is a prescription inhaled corticosteroid medicine used for the prevention and control of asthma symptoms in people aged 5 and over. It is not for use in treating sudden severe asthma symptoms. ASMANEX HFA should not be used as a rescue inhaler."

Answered by AI

Is Asmanex HFA discontinued?

"Asmanex Twisthaler is not available in the United States as an equivalent therapeutic version. Fraudulent online pharmacies may attempt to sell a generic version of Asmanex Twisthaler illegally. These medications may be counterfeit and potentially unsafe."

Answered by AI

Clinical Trials for Asmanex Hfa

Image of Waianae Coast Comprehensive Health Center in Waianae, United States.

Community Program for Youth Well-Being

12 - 25
All Sexes
Waianae, HI

The goal of this pilot clinical trial is to learn if a community referral program can improve services for youth with mental health and chronic health conditions in a predominantly Native Hawaiian and Pacific Islander community. The main questions the trial aims to address are: * What is the best way for a community health center to connect youth with community programs rooted in cultural practices and traditions? * Does participation in community programs engage youth and mental health and chronic health outcomes? Participants will: * Participate in a community program for youth that will strengthen connection to 'āina (land) and culture. Programs in the summer are 5 hours per day, 4 days a week, for 4 weeks. Programs in the school-year are 2.5 hours per day, 2 days a week, for 16 weeks. * Take surveys on their demographics, general well-being, mental health, and chronic health conditions they may have at 4 different times: Before the program begins, immediately after the program finishes, 3-4 months after finishing, and 6-8 months after finishing. * Have an adult family member complete surveys on their youth's demographics and general well-being at the same 4 times

Recruiting
Has No Placebo

Waianae Coast Comprehensive Health Center

May M Okihrio, MD, MS

Have you considered Asmanex Hfa clinical trials?

We made a collection of clinical trials featuring Asmanex Hfa, we think they might fit your search criteria.
Go to Trials
Image of San Francisco VA Medical Center in San Francisco, United States.

Dietary Salt for Eczema

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: * Does a low-sodium diet improve eczema severity? * How does a low-sodium diet impact skin sodium concentration? * Is skin sodium concentration associated with eczema severity? Researchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: * Follow a low-salt diet for the duration of the 24-week study * Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa * Complete up to 4 virtual check-in visits * Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

Phase 4
Waitlist Available

San Francisco VA Medical Center (+1 Sites)

Katrina Abuabara, MD

Image of Corvus Clinical Trials in South San Francisco, United States.

Soquelitinib for Eczema

18+
All Sexes
South San Francisco, CA

The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study. The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them. To understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it. Participants will: * Take study treatment (soquelitinib or placebo) every day for 12 weeks * Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment

Phase 2
Recruiting

Corvus Clinical Trials

Isin Sinem Bagci, MD

Corvus Pharmaceuticals, Inc.

Have you considered Asmanex Hfa clinical trials?

We made a collection of clinical trials featuring Asmanex Hfa, we think they might fit your search criteria.
Go to Trials
Image of ALS Global in Irving, United States.

GX-03 for Eczema

18 - 80
All Sexes
Irving, TX

This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Subjects will be randomized in a 1:1 ratio to receive either GX-03 or vehicle control for 8 weeks. The study is designed to evaluate improvement in investigator-assessed disease severity, itch, and patient-reported eczema symptoms following topical treatment with GX-03 compared with vehicle control. Efficacy assessments include the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), Eczema Area and Severity Index (EASI), Peak Pruritus Numeric Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM). An interim assessment of conditional power for the primary efficacy endpoint will occur after the first 50 subjects complete the Week 8 visit or withdraw prematurely. Based on pre-specified criteria defined in the IDMC Charter, the IDMC may recommend continuation as planned, expansion of enrollment up to 200 subjects, or early curtailment of enrollment.

Phase 2
Recruiting

ALS Global

Turn Therapeutics

Image of Seeding Labs INC in Austin, United States.

Tailored Recommendations for Infant Gut Microbiome

No minimum age - 3
All Sexes
Austin, TX

The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms. Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model. Participants will: 1. Provide six microbiome stool samples over a 24-month period. 2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis. 3. Receive microbiome reports and guidance according to their assigned study arm. 4. Complete surveys on infant health history, symptoms, diet, and environmental exposures. 5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported. This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.

Recruiting
Has No Placebo

Seeding Labs INC

Qian Yuan, MD

Seeding, Inc DBA Tiny Health

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Verified
Image of Velocity Clinical Research - Medford in Medford, United States.

ENV-294 for Asthma

18 - 75
All Sexes
Medford, OR

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

Phase 2
Recruiting
Quick Reply

Velocity Clinical Research - Medford (+11 Sites)

Gurpreet Ahluwalia, PhD

Enveda Therapeutics

Have you considered Asmanex Hfa clinical trials?

We made a collection of clinical trials featuring Asmanex Hfa, we think they might fit your search criteria.
Go to Trials